Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Pralmorelin (GHRP-2) vs GHRP-6 (Growth Hormone Releasing Peptide-6) — Peptide Comparison

At a Glance Quickcomparison Dose Range Pralmorelin (GHRP-2) 100–300 mcg GHRP-6 (Growth Hormone Releasing Peptide-6) Frequency Once daily Multiple times daily Administration Subcutaneous injection Cycle Length 4-6 weeks 8-12 weeks Onset Speed Rapid (hours to da

At a Glance

Quickcomparison

Dose Range

Pralmorelin (GHRP-2)

100–300 mcg

GHRP-6 (Growth Hormone Releasing Peptide-6)

Frequency

Once daily

Multiple times daily

Administration

Subcutaneous injection

Cycle Length

4-6 weeks

8-12 weeks

Onset Speed

Rapid (hours to days)

Moderate (1-2 weeks)

Evidence Level

Limited human trials

Efficacy

Benefitratings

Muscle & Performance Enhancement

Injury Recovery & Healing

Diagnostic Clinical Use

Muscle Recovery and Growth

Cellular Health and Protection

Appetite and Nutrient Intake

Technical Data

Compoundspecifications

Molecular Formula

C45H55N9O6

Molecular Weight

818.0 g/mol

Half-Life

15-60 minutes

Bioavailability

~100% (subcutaneous injection)

CAS Number

158861-67-7

C46H56N12O6

873.0 g/mol

~2.5 hours

<1% oral, high subcutaneous

87616-84-0

Protocols

Dosingtiers

standard

1 mcg/kg/hour (continuous infusion) in research settings

Continuous infusion

Study-defined (e.g. ~270 minutes in published trials)

Subcutaneous infusion dose used in controlled human GH-release/appetite studies; not an approved therapeutic regimen. [4]

100 mcg (0.1 mg) single bolus (diagnostic GH-stimulation test)

Single administration

Single test; blood sampled at 0, 15, 30, 60 min

Japan-approved diagnostic dose (GHRP Kaken 100) for growth hormone deficiency; fixed 100 mcg IV bolus. A research GH-stimulation dose of 1 mcg/kg IV is also documented. [1]

~100 mcg per injection (approx. 1 mcg/kg)

1-3 times daily, on an empty stomach

Open-ended in research practice

Research-practice GH-secretagogue dosing; the ~100 mcg anchor reflects the validated 1 mcg/kg GH-saturating dose, though no isolated subcutaneous human dose-response trial exists [6].

1 mcg/kg bolus (optionally followed by 1 mcg/kg/hr infusion)

Single bolus for acute GH testing; infusion studies ran up to ~34 hours

Acute test or infusion study

Trial-established near-maximal GH-releasing intravenous dose in healthy men; pituitary responsiveness maintained over prolonged infusion [6].

Applications

Bestsuited for

Athletes and Fitness Enthusiasts

If you're serious about lean muscle gains and recovery, pralmorelin directly stimulates GH release—one of the body's most powerful anabolic hormones. Most athletes in research settings use 100-200 mcg for faster muscle repair and improved performance.

Individuals Recovering from Injury

Recent animal studies show GHRP-2 reduces inflammation and speeds tendon-bone healing. If you're dealing with sports injuries, rotator cuff issues, or fractures, this peptide's anti-inflammatory profile may accelerate recovery when combined with proper rehab.

Those Seeking Diagnostic GH Testing

If your doctor suspects growth hormone deficiency, pralmorelin is the gold-standard diagnostic tool in Japan and many countries. A single injection stimulates GH release, allowing physicians to assess your pituitary function safely and accurately.

Peptide Research Enthusiasts

Pralmorelin is one of the most extensively studied GHRPs worldwide. If you're exploring peptide protocols and understand research-grade products, this is a powerful tool for understanding how your GH axis responds to stimulation.

Athletes and Serious Trainers

If you're hitting the gym hard and want better recovery and muscle growth, GHRP-6 amplifies your body's natural GH response. This is particularly valuable during intense training phases when you want to maximize adaptation and minimize soreness. The appetite stimulation also helps you consume the calories you need to grow.

Those Exploring Novel Peptide Protocols

GHRP-6 offers a unique mechanism through the ghrelin receptor, making it valuable for users who want to explore diverse GH-stimulation pathways. It works distinctly from GHRH-based approaches and pairs well with other GH secretagogues for synergistic effects.

Longevity and Metabolic Health Enthusiasts

Growth hormone plays roles in metabolic health, body composition, and potentially aging markers. GHRP-6's emerging research on cellular protection and antioxidant activation makes it interesting for those interested in broader health optimization beyond just muscle growth.

Safety Profile

Sideeffects

Common

Facial flushing

Transient headache

Increased appetite

Temporary dizziness or lightheadedness

Uncommon

Carpal tunnel-like sensations

Joint or muscle aches

Sleep quality changes

Serious

Severe allergic reaction (anaphylaxis)

Increased Appetite

Mild Joint or Muscle Discomfort

Water Retention or Mild Swelling

Sleep Disturbances

Mild Dizziness or Lightheadedness

Allergic Reaction

Research Status

Safety& evidence

FDA Status

Research compound

Safety Overview

Pralmorelin (GHRP-2) has been safely used in diagnostic settings in Japan for decades and is well-tolerated in most individuals when used at appropriate doses. The peptide is synthetic and chemically stable, with low immunogenicity risk. However, it is NOT FDA approved and should only be used under medical supervision or within research protocols. Long-term safety data in healthy humans is limited.

Contraindications

xActive malignancy or unresolved cancer history

xUncontrolled hypertension or severe cardiovascular disease

xPregnancy or breastfeeding

xAcute infection or sepsis

xUncontrolled diabetes

GHRP-6 has a relatively long research history dating back to 1981, with human studies demonstrating its ability to stimulate GH release. The good news is that animal safety studies show excellent tolerability at high doses, and the side effects reported are generally mild and reversible. However, it's not FDA-approved, so use is based on research evidence rather than pharmaceutical oversight. Always purchase from reputable sources and consider medical consultation, especially if you have existing health conditions.

xKnown allergy or sensitivity to any component of the peptide

xActive cancer or history of cancer without medical clearance

xSevere cardiovascular disease or uncontrolled hypertension

xAcute critical illness or sepsis

Decision Guide

Which isright for you?

Choose Pralmorelin (GHRP-2) if...

Athletes seeking enhanced recovery and lean mass gains

Individuals with suspected GH deficiency (diagnostic use)

Recovery from tendon or bone injuries

Those wanting to test GH axis responsiveness

Choose GHRP-6 (Growth Hormone Releasing Peptide-6) if...

Building lean muscle mass and improving body composition

Recovery from intense training programs and athletic performance

Supporting overall metabolic health and longevity markers

Exploring novel GH-stimulation pathways for those who respond well to peptide protocols

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

GHRP-2 vs. GHRP-6: What Research Reveals About Two Classic GH Secretagogues

GHRP-2 and GHRP-6 belong to the classic group of synthetic peptides known as growth hormone secretagogues - compounds studied for their ability to stimulate the body’s natural release of growth hormone (GH). Both molecules act through the GHS-R receptor, also known as the ghrelin receptor, which is why they have long attracted attention in endocrinology and metabolic research. Although they share many similarities, scientific literature suggests that their biological profiles are not entirely identical. Researchers are interested in these peptides for more than GH stimulation alone. Because the ghrelin receptor is also linked to appetite regulation, energy balance, neuroendocrine signaling, and several peripheral functions, both GHRP-2 and GHRP-6 are being investigated beyond their role as simple “growth hormone triggers.” For this reason, comparative studies often focus not only on the magnitude of GH release, but also on differences in appetite, hormonal response, and metabolic context. What Are GHRP-2 and GHRP-6? GHRP-2, also known as pralmorelin, is a synthetic hexapeptide developed as a growth hormone secretagogue. GHRP-6 belongs to the same category and is historically one of the oldest and most extensively studied GH secretagogues. Both molecules were designed to explore whether the pituitary gland could be stimulated to release GH in a pulsatile manner without directly administering exogenous growth hormone itself. Mechanistically, both compounds are notable because they do not act through the classical GHRH receptor pathway, but through GHS-R1a, the receptor for ghrelin. This means their effects are tied to a physiological system naturally associated not only with growth hormone regulation, but also with hunger, energy adaptation, and neuroendocrine responses. How Do They Work According to Scientific Studies? Scientific studies show that both GHRP-2 and GHRP-6 stimulate growth hormone secretion from the anterior pituitary gland and may also influence the somatostatin inhibitory pathway, which normally suppresses GH release. As a result, both peptides produce a pulsatile GH response. From a research perspective, this pattern is particularly interesting because it more closely resembles natural GH physiology than continuous administration of exogenous hormone. Despite their similar mechanism of action, comparative studies have shown that GHRP-2 is generally considered a more potent GH stimulator than GHRP-6. Early experimental studies using pituitary cell models demonstrated that although both peptides rely on related mechanisms, the intensity of the hormonal response differs between them. The Most Important Difference: GH Potency From a purely endocrine research perspective, GHRP-2 is frequently described in the literature as the more potent growth hormone secretagogue. This distinction has been observed not only in experimental models but also in human hormonal studies. Because of this, GHRP-2 was historically investigated as a tool for evaluating pituitary function and GH reserve. This does not mean that GHRP-6 is “weak.” On the contrary, GHRP-6 has also demonstrated a strong ability to stimulate GH release. However, scientific literature more commonly emphasizes its broader connection to the ghrelin system and its metabolic implications. GHRP-6 and the Ghrelin-Like Profile In scientific studies, GHRP-6 is very often associated with more pronounced mimicry of certain orexigenic effects of ghrelin—signals related to hunger and food intake. Experimental research has shown that GHRP-6 can stimulate food intake in a manner similar to ghrelin, which represents one of the most well-known distinctions between it and GHRP-2. Human studies have also observed increased appetite and food intake with GHRP-2. The difference is that with GHRP-6, this effect is more consistently described in the literature as a defining characteristic of its biological profile. A Broader Hormonal Response Comparisons between these peptides do not focus solely on GH release. Human studies have shown that some GH secretagogues, including GHRP-2, may also influence additional hormones such as prolactin, ACTH, and cortisol. This suggests that these compounds produce a broader neuroendocrine effect rather than an isolated action on a single hormonal axis. This wider hormonal impact is one reason why GHRP-2 is often described in the literature as “stronger,” but also more complex in terms of endocrine response. GHRP-6 likewise has systemic effects, although greater emphasis is typically placed on ghrelin signaling, food intake, and peripheral metabolic actions. GHRP-2 and GHRP-6 in Combination With GHRH Research on GH secretagogues has repeatedly shown that these peptides cannot be fully separated from the GHRH pathway. Experimental models demonstrate that combining GHRPs with GHRH may lead to significantly greater GH release than activating either pathway alone. This synergistic principle has also been described for both GHRP-2 and GHRP-6 and is important for understanding the physiological regulation of growth hormone secretion. What Does This Mean From a Scientific Comparison Perspective? If the literature were summarized very briefly, GHRP-2 is more commonly described as a stronger stimulator of GH secretion, whereas GHRP-6 is often presented as a peptide with a more pronounced relationship to ghrelin signaling, appetite regulation, and metabolic control. The two molecules are closely related, but they are not fully interchangeable because they do not produce identical biological response profiles. From a scientific standpoint, the key question is therefore not which peptide is “better,” but rather what type of hormonal and metabolic response researchers aim to study. For investigations involving the ghrelin receptor, energy intake, and orexigenic signaling, GHRP-6 is particularly interesting. In endocrine models focused on stronger GH stimulation, GHRP-2 is more frequently discussed. Conclusion GHRP-2 and GHRP-6 have played an important role in research involving growth hormone regulation, the ghrelin receptor, and neuroendocrine signaling. Although both molecules stimulate GH release through related receptor mechanisms, scientific literature describes clear functional differences between them. GHRP-2 is associated with a stronger GH response and broader hormonal activity, whereas GHRP-6 is more commonly linked to ghrelin signaling, appetite regulation, and metabolic processes. For this reason, both peptides remain valuable primarily as research tools that help scientists better understand how the body regulates growth hormone secretion, hunger, and energy balance. Sources Cheng J. et al. (1997). Growth Hormone Releasing Peptides: A Comparison of the Growth Hormone Releasing Activities of GHRP-2 and GHRP-6 in Rat Primary Pituitary Cells. Life Sciences. PubMed. Wu D. et al. (1996). The Effects of GH-Releasing Peptide-6 (GHRP-6) and GHRP-2 on GH Release. Peptides. PubMed. Arvat E. et al. (1997). Effects of GHRP-2 and Hexarelin, Two Synthetic GH-Releasing Peptides, on GH, Prolactin, ACTH and Cortisol Levels in Man. European Journal of Endocrinology. PubMed. Bennett K.A. et al. (2009). Growth Hormone Secretagogues and Growth Hormone-Releasing Hormone Interactions. PMC Review. Yin Y. et al. (2014). The Growth Hormone Secretagogue Receptor: Its Intracellular Signaling and Regulation. International Journal of Molecular Sciences. PMC. Laferrère B. et al. (2005). Growth Hormone-Releasing Peptide-2 (GHRP-2), Like Ghrelin, Increases Food Intake in Healthy Men. JCEM-linked literature. Yahashi S. et al. (2012). GHRP-6 Mimics Ghrelin-Induced Stimulation of Food Intake. PubMed. Gondo R.G. et al. (2001). Growth Hormone-Releasing Peptide-2 Stimulates GH and ACTH Secretion. JCEM / PubMed indexed.

POTENTIAL BENEFITS

Primary Benefits

GHRP-2 directly stimulates GH release, amplifying training response and accelerating lean mass development. Athletes and serious lifters report faster recovery, improved workout capacity, and visible lean mass gains over 4-6 week cycles. Research suggests GHRP-2 reduces inflammation and supports tissue repair through anti-inflammatory mechanisms. Those recovering from sports injuries, surgical procedures, or chronic soft tissue issues report faster healing timelines. GHRP-2 is the gold-standard diagnostic peptide for assessing growth hormone deficiency. A single injection reliably stimulates GH release (or fails to in GH-deficient patients), enabling physicians to diagnose GH axis disorders with high accuracy.
05

Product & matchup locker

Linked catalog and comparison files.